Medicare Advantage

The Trump administration’s recent Medicare Advantage posture is pairing a more favorable-than-feared MA payment update with tighter scrutiny of Stars, risk adjustment, and coding integrity, keeping MA central to value-based care economics while raising compliance and revenue-cycle stakes for plans and delegated providers. CMS’s 2027 MA/Part D final rule realigns Star Ratings incentives, including changes analyzed by Wakely in “When Stars Realign”, while litigation over Star Ratings, DOJ activity involving MA risk-adjustment practices, and Aetna’s $117.7 million false-claims settlement reinforce that quality bonuses and diagnosis-driven revenue remain contested strategic terrain. For ACOs, risk-bearing medical groups, and payer partners, the near-term signal is not retreat from MA growth but a shift toward more defensible documentation, audit readiness, quality-measure performance, and tighter governance of in-home assessments and chart-review programs as MA’s scale increasingly shapes Medicare’s overall performance.